Atlanta, GA – Scibility Media – 11/07/2014.
This article discusses two companies: UQM Technologies Inc(NYSEMKT:UQM) and Hospira, Inc.(NYSE:HSP)
UQM Technologies Inc(NYSEMKT:UQM) reported its second quarter operating results after the markets closed on Nov. 5th, 2014. The results could have been significantly stronger for UQM Technologies. In addition to reporting a revenue figure of $1.1 million, a $0.9 from the same period during the previous fiscal year, the Colorado-based company also announced a net loss of $2.0 million for the second quarter, or $0.05 per common share. The severity of that figure is exposed when considering its figures for the previous second quarter: a net loss of $0.4 million, or $0.01 per common share. UQM Technologies develops and sells electric motors and power electronic controllers.
Hospira, Inc.(NYSE:HSP) is an Illinois-based generic drugs company that provides injectable pharmaceutical drugs and infusion technologies through the Americas, EMEA, and APAC segments. On Nov. 5th, the company announced that it had launched its Paricalcitol Injection, which is a generic version of AbbVie’s Zemplar.
Yesterday, Hospira reported its third quarter 2014 financial results. The reported figures included a net sales number of $1.2 billion and an adjusted earnings per share of $0.74. On a GAAP basis, the company recorded a diluted earnings per share of $0.92. Hospira’s Chief Executive Officer, F. Michael Ball, stated that the company was “very pleased with Hospira’s performance in the third quarter, one of our stronger quarters in recent history.”
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to email@example.com and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.